Across 18,965 adults enrolled in a national virtual medical nutrition therapy (vMNT) platform, six months of registered-dietitian-led telehealth visits produced statistically significant improvements in every measured cardiometabolic marker: LDL cholesterol fell 14.0 mg/dL, total cholesterol 19.4 mg/dL, and triglycerides 28.6 mg/dL; systolic blood pressure dropped 5.5 mmHg and diastolic 4.5 mmHg; HbA1c declined 1.37 percentage points. Clinically, 57.3% of hypertensive patients reached the <130 mmHg target and 54.7% of diabetic patients reached HbA1c <7.0%. Effects were similar among those on stable medications, suggesting diet — not drug titration — drove the gains.
These effect sizes are meaningful by clinical benchmarks: a 14 mg/dL LDL reduction approximates the benefit of a low-intensity statin, and a 1.4-point HbA1c drop rivals many glucose-lowering medications. The real-world scalability angle is also notable, addressing a genuine gap where guideline-recommended MNT is rarely reimbursed or accessed. However, several important limitations temper enthusiasm. This is a retrospective cohort with no control arm, so regression to the mean, selection bias among motivated patients, and loss-to-follow-up (only those with ≥1 follow-up measurement were included) could substantially inflate apparent benefits. The cohort skews heavily female (83%) and relatively young (mean age 43). As a preprint not yet peer-reviewed, the findings require independent validation before influencing clinical practice. Overall, this is a promising large-scale signal that virtual dietitian care warrants a well-controlled randomized trial.